card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Alzheimer’s Disease Clinical Trials

Innovative laboratory solutions to accelerate progress
Home / Insights / Alzheimer’s Disease Clinical Trials

Over 55 million people worldwide were suffering of dementia in 2020. This number is expected to almost double every 20 years, reaching 78 million in 2030 and rising to 139 million in 2050.4 The worldwide cost of dementia is estimated at US$1.3 trillion and is expected to rise to US$ 2.8 trillion by 2030.

 

Alzheimer’s disease (AD) remains an area of severe unmet need and decades of research, but significant progress was recently made with innovative treatments. Following the FDA approval aducanumab (Leqembi™) from Eisai and donanenab-azbt (Kisunla™) from Eli Lilly1,2 aiming at addressing underlying disease biology are now marketed. Similarly, impactful advancement was made in the discovery and the validation of laboratory tests to assist with disease diagnostics and to evaluate disease progression.

 

Download our insight brief and learn about the potential to advance Alzheimer’s Disease trials through advanced neurodegenerative disease reference testing services and validation of innovative diagnostic biomarkers.

 

Authors:
PATRICE HUGO, Ph. D., Chief Scientific Officer, IQVIA Laboratories and R&DS Design and Deliver Innovation
MAREK BIENIEK, MD, MS, Sr. Director Medical Strategy, CNS Center of Excellence, R&DS Design and Delivery Innovation

 

Complete the form below to access this insight brief